Search Within

Tala Shekarkhand

Formats
  1. Meeting Abstract (34)
  2. Journal Article (7)
  3. Research Letter (2)
  4. Correspondence (1)
Groups
  1. Hematologic Malignancies, Division of (44)
  2. Center for Hematologic Malignancies (43)
  3. Department of Medicine (43)
  4. Hematologic Malignancies Research (43)
  5. Myeloma (43)
  6. CTCR Scholars (41)

More Groups

People
  1. Alexander Lesokhin (43)
  2. Carlyn Rose Tan (41)
  3. Hani Hassoun (41)
  4. Malin Hultcrantz (41)
  5. Sham Mailankody (41)
  6. Urvi Shah (41)

More People

Years
  1. 2025 (2)
  2. 2024 (22)
  3. 2023 (13)
  4. 2022 (3)
  5. 2021 (1)
  6. 2020 (2)

More Years

Publications
  1. Blood (21)
  2. Clinical Lymphoma, Myeloma and Leukemia (12)
  3. Blood Advances (3)
  4. Blood Cancer Journal (2)
  5. Journal of Clinical Oncology (2)
  6. Blood Neoplasia (1)

More Publications

Publishers
  1. American Society of Hematology (24)
  2. Elsevier Inc. (13)
  3. American Society of Clinical Oncology (2)
  4. Nature Publishing Group (2)
  5. American Association for Cancer Research (1)
  6. American Medical Association (1)

More Publishers

Results (44)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Defining the rates of cytokine release syndrome associated with Talquetamab step-up doses
    Meeting Abstract

    Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Whole genome sequencing reveals lower APOBEC-mutational activity in multiple myeloma patients with African ancestry compared with those of non-African ancestry
    Meeting Abstract

    Maclachlan, K.; Papadimitriou, M.; Blaney, P.; McPherson, A.; Chu, T.; Diamond, B.; Ziccheddu, B.; Shekarkhand, T.; Poos, A.; Brown, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Comprehensive genomic sequencing predicts sub-optimal response to bispecific antibodies (BsAb) and chimeric antigen receptor T cells (CAR-T) in multiple myeloma (MM)
    Meeting Abstract

    Maclachlan, K.; Shekarkhand, T.; Farzana, T.; Costa, B.; Firestone, R.; Jurgens, E.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of granulocyte colony-stimulating factor exposure on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma
    Meeting Abstract

    Wang, A.; Shekarkhand, T.; Derkach, A.; Nemirovsky, D.; Tan, C.; Hamadeh, I.; Firestone, R.; Jurgens, E.; Miller, K.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Real world experience of talquetamab in relapsed refractory myeloma, first report from the IMWG Consortium
    Meeting Abstract

    Janakiram, M.; Tan, C.; Popat, R.; Kastritis, E.; Martínez-Lopez, J.; Shekarkhand, T.; Bansal, R.; De Menezes Silva Corraes, A.; de la puerta, M. C.; Sáez Marín, A. J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • CMV reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E.; Shekarkhand, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R.; Miller, K.; Costa, B.; Rajeeve, S.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Tan, C.; Shekarkhand, T.; Firestone, R.; Jurgens, E.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; Rajeeve, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Para-medullary (PMD) and extra-medullary (EMD) myeloma demonstrate increased copy number aberration, mutational burden, structural variants and genomic complexity compared to marrow-based myeloma
    Meeting Abstract

    Maclachlan, K.; Garcés, J. J.; Shekarkhand, T.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Tan, C.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
    Research Letter

    Hultcrantz, M.; Hassoun, H.; Korde, N.; MacLachlan, K.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C. R.; Chung, D. J.; Lahoud, O. B.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of retreatment with daratumumab-based regimens in anti-CD38 refractory multiple myeloma
    Meeting Abstract

    Tan, C. R. C.; Rueda, C.; Shekarkhand, T.; Derkach, A.; Korde, N.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save